Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma

Hematological Oncology

Volumn 24, Issue 3, 2006, Pages 97-104

  Muris, Jettie J F ^a   Meijer, Chris J L M ^a   Ossenkoppele, Gert J ^a   Vos, Wim ^a   Oudejans, Joost J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; B cell lymphomas; Clinical outcome; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 10; DOXORUBICIN; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; GRANZYME B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; PROTEIN BCL 2; PROTEIN P16INK4A; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; B CELL LYMPHOMA; CANCER REGRESSION; CANCER RELAPSE; CELL DEATH; COMBINATION CHEMOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DIFFUSE LARGE B CELL LYMPHOMA; DNA DAMAGE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; LARGE CELL LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33749243745     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.774     Document Type: Review

References (101)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Kuppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999; 341: 1520-1529.
3. Lossos IS, Alizadeh AA, Eisen MB, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000; 97(18): 10209-10213.
4. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997; 90(6): 1073-1083.
5. Mckelvey EM, Gottlieb JA, Wilson HE. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-1493.
6. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14: 520-535. Review.
7. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
8. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic physiological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
9. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997; 91: 443-446.
10. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol 1999; 17: 781-828.
11. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002; 2: 401-409.
12. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85(6): 817-827.
13. Juo P, Kuo CJ, Yuan J, Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 1998; 8(18): 1001-1008.
14. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999; 68: 383-424. Review.
15. Stennicke HR, Jurgensmeier JM, Shin H, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998; 273(42): 27084-27090.
16. Waterhouse NJ, Sedelies KA, Browne KA, et al. A central role for Bid in granzyme B-induced apoptosis. J Biol Chem 2005; 280(6): 4476-4482.
17. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001; 1: 50-58.
18. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80(2): 293-299.
19. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998; 95(9): 4997-5002.
20. Soengas MS, Alarcon RM, Yoshida H, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999; 284(5411): 156-159.
21. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91(4): 479-489.
22. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999; 59(Suppl. 7): 1693s-1700s.
23. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25-35.
24. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 1994; 370(6491): 650-652.
25. Kagi D, Vignaux F, Ledermann B, et al. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265(5171): 528-530.
26. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375(6526): 78-81.
27. Monaco JJ. A molecular model MHC class-I-restricted antigen presentation. Immunol Today 1992; 13: 173-179.
28. Rees C, Mian S. Selective MHC expression in tumors modulates adaptive and innate antitumor responses. Cancer Immunol Immunother 1999; 48: 374-381.
29. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002; 2: 401-409.
30. Kagi D, Ledermann B, Burki K. Cytotoxicity mediated by T-cells and natural killer cells is greatly impaired perforin-deficient mice. Nature 1994; 361: 31-37.
31. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995; 377: 446-448.
32. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195(2): 161-169.
33. Rubio-Moscardo F, Blesa D, Mestre C, et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 2005; 106(9): 3214-3222. Epub 2005 Jul 28.
34. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-818.
35. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70. Review.
36. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001; 1: 50-58.
37. Shin MS, Kim HS, Kang CS, et al. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 2002; 99(11): 4094-4099.
38. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
39. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8(1): 68-74.
40. Rosenwald A, Wright G, Chan WC, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(25): 1937-1947.
41. Muris J, Meijer C, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006 Apr; 208(5): 714-723.
42. Gombart AF, Morosetti R, Miller CW, Said JW, Koeffler HP. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. Blood 1995; 86(4): 1534-1539.
43. Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91(8): 2977-2984.
44. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003; 13: 77-83.
45. Raaphorst FM, Otte AP, Meijer CJ. Polycomb-group genes as regulators of mammalian lymphopoiesis. Trends Immunol 2001; 22: 682-690.
46. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene BMI1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397: 164-168.
47. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. BMI1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999; 13: 2678-2690.
48. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphoma-genesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13(20): 2670-2677.
49. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Eischen cm Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13(20): 2658-2669.
50. Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337: 529-534.
51. Bea S, Colomo L, Lopez-Guillermo A, Salaverria I, Puig X, Pingol M, Rives S, Montserrat E, Campo E. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004; 22(17): 3498-3506.
52. Leroy K, Haioun C, Lepage E, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002; 13(7): 1108-1115.
53. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS. NF-kappa B anti-apoptosis induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-1683.
54. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20: 2687-2695.
55. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90(1): 244-251.
56. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92(9): 3152-3162.
57. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997; 90(3): 1168-1174.
58. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998; 92(1): 234-240.
59. Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106(4): 1392-1399.
60. Houldsworth J, Olshen AB, Cattoretti G, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood 2004; 103(5): 1862-1868. Epub 2003 Nov 13.
61. Rothstein TL. Inducible resistance to Fas-mediated apoptosis in B cells. Cell Res 2000; 10(4): 245-266. Review.
62. van Eijk M, Defrance T, Hennino A, de Groot C. Death-receptor contribution to the germinal-center reaction. Trends Immunol 2001; 22(12): 677-682. Review.
63. Muris JJ, Cillessen SA, Vos W, et al. Immuno-histochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005; 105(7): 2916-2923.
64. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996; 381: 751-758. Review.
65. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408(6810): 307-310.
66. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22(56): 9030-9040. Review.
67. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002; 4(11): 859-864.
68. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92(9): 3152-3162.
69. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69(1): 119-128.
70. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12(15): 2424-2433.
71. Klefstrom J, Verschuren EW, Evan G. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. J Biol Chem 2002; 277(45): 43224-43232. Epub 2002 Aug 28.
72. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002; 1(3): 289-298.
73. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002; 109(3): 321-334.
74. Muris JJ, Meijer CJ, Cillessen SA, et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004; 18(3): 589-596.
75. Riemersma SA, Jordanova ES, Schop RFJ, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000; 96: 3569-3577.
76. Mingari MC, Schiavetti F, Ponte M, et al. Human CD8+ T lymphocyte subsets that express HLA I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci USA 1996; 93: 12433-12438.
77. Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150: 1147-1159.
78. Bird CH, Sutton VR, Sun J, et al. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 1998; 18: 6387-6398.
79. Sun J, Bird CH, Sutton V, et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996; 271: 27802-27809.
80. Goping IS, Barry M, Liston P, et al. Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. Immunity 2003; 18: 355-365.
81. Oudejans JJ, ten Berge RL, Meijer CJ. Immune escape mechanisms in ALCL. J Clin Pathol 2003; 56(6): 423-425.
82. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-272.
83. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136-1143.
84. Kramer MH, Hermans J, Parker J, et al. Clinical significance of Bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996; 14: 2131-2138.
85. Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005; 106(5): 1770-1777. Epub 2005 May 10.
86. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005; 436: 807-811.
87. Carter BZ, Gronda M, Wang Z, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 2005; 105(10): 4043-4050.
88. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003; 3030: 133-142.
89. Tolcher AW. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Clin Adv Hematol Oncol 2005; 3(8): 635-642, 662. Review.
90. Walensky LD, Kung AL, Escher I, andere auteurs. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305: 1466-1470.
91. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99(11): 4079-4086.
92. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
93. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98: 795-804.
94. Georgakis GV, Li Y, Humphreys R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005; 130(4): 501-510.
95. Lee SH, Shin MS, Kim HS, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001; 20(3): 399-403.
96. Berglund M, Enblad G, Flordal E, et al. Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization. Mod Pathol 2002; 15(8): 807-816.
97. Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 2004; 109(5): 786-792.
98. Muschen M, Rajewsky K, Kronke M, Kuppers R. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol 2002; 23(2): 75-80. Review.
99. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90(1): 244-251.
100. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 2000 Jan 6; 403 (6765): 98-103.
101. Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem. 2002 Sep 13; 277(37): 34287-94. Epub 2002 Jul 3.